Finerenone Heart Failure Treatment Recommended for Thousands in England
A new treatment option is set to become available for thousands of people in England living with a common type of chronic heart failure, following the latest recommendation for finerenone.
Introduction
Finerenone heart failure treatment has been recommended for adults in England with chronic heart failure with preserved or mildly reduced ejection fraction, offering a new option on the NHS. Final draft guidance supports its use for this group, with final guidance expected in August 2026.
What Preserved or Mildly Reduced Ejection Fraction Means
Heart failure with preserved or mildly reduced ejection fraction occurs when the left side of the heart does not fill properly with blood during the diastolic, or filling, phase. This means the heart is unable to pump enough blood to meet the body’s needs. In this type of heart failure, the reduction in blood pumped is smaller than in heart failure with reduced ejection fraction.
Symptoms and Impact on Patients
Heart failure can cause symptoms including breathlessness, fatigue and ankle swelling. People with the condition often need to be admitted to hospital, which can have a significant impact on their quality of life and independence. Many people with chronic heart failure also live with other long-term conditions, including chronic kidney disease, diabetes and high blood pressure, which can make treatment more complex.
How Finerenone Works
Finerenone is a type of treatment called a mineralocorticoid receptor antagonist, or MRA. Unlike other MRAs, finerenone is nonsteroidal, which means it may be suitable for more people.
Potential Benefits for the NHS
The treatment has the potential to help people live well for longer. It could also save the NHS money and free up space by reducing the risk of patients needing to attend hospital for unplanned emergency treatment.
Who Is Eligible
Of the estimated 635,000 people in England who have heart failure, half have preserved or mildly reduced ejection fraction. There were around 100,000 hospitalisations in England for heart failure in 2023 to 2024, making it one of the leading causes of avoidable hospital admissions. It is estimated that up to 280,000 people could be eligible for finerenone.
Conclusion
This finerenone heart failure treatment recommendation marks a further effective option for adults in England with preserved or mildly reduced ejection fraction. With final guidance expected in August 2026, the decision has the potential to improve outcomes for a large patient group while reducing pressure on hospital services.
Citation
Recent Resources
